<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02000388</url>
  </required_header>
  <id_info>
    <org_study_id>1012-2011-SPRIX</org_study_id>
    <nct_id>NCT02000388</nct_id>
  </id_info>
  <brief_title>Intranasal Ketorolac Tromethamine (SPRIX) as a Short Term Pain Management of Post-Vasectomy Pain</brief_title>
  <official_title>Efficacy and Safety of Intranasal Ketorolac Tromethamine (SPRIX) as a Short Term Pain Management Tool for Adult Male Patients With Post-Vasectomy Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Citrus Valley Medical Research, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Citrus Valley Medical Research, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy, tolerability and safety of intranasal ketorolac tromethamine
      (SPRIX) as an option for pain management in post vasectomy patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Scores on the Visual Analog Scale</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>5 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Post Vasectomy Pain</condition>
  <arm_group>
    <arm_group_label>Ketorolac tromethamine (SPRIX)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A SPRIX dose will be one 15.75 mg spray in each nostril for a total dose of 31.5 mg which can be repeated every 6-8 hrs as needed for post vasectomy pain with a maximum daily dose of 126 mg to be continued for up to 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The intervention used will be standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac Tromethamine</intervention_name>
    <arm_group_label>Ketorolac tromethamine (SPRIX)</arm_group_label>
    <other_name>SPRIX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <arm_group_label>Standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA

          1. Male Subject must be between the age twenty five (25) years and sixty four (64)

          2. Willing and able to provide an informed consent

          3. Has made decision to undergo vasectomy

          4. Subject is in good general physical condition as assessed by the Principal
             Investigator

        EXCLUSION CRITERIA

          1. Current treatment with or known allergy or sensitivity to all forms of ketorolac
             tromethamine , aspirin , other non steroidal anti inflammatory drugs (NSAIDs) or
             Ethylenediaminetetraacetic acid (EDTA)

          2. Use of narcotics/opiate or medical marijuana within one (1) week prior to the baseline
             visit and entire study participation

          3. Use of illegal drugs by self reporting

          4. History of drug or alcohol abuse within five (5) years of screening visit

          5. History of suicide attempt within five (5) years of screening visit

          6. A diagnosis of a severe neuro-psychiatric disease

          7. Subject who is currently receiving investigational drug(s) or participated in a
             clinical trial involving investigational drug(s) within thirty (30) day of the
             screening visit

          8. Subject with history of any of the following coronary conditions: (chronic stable
             angina being currently treated with long acting nitrates, chronic stable angina
             require treatment with short acting nitrates with 90 days of visit 1, angina occurring
             during sexual intercourse in the last six months, unstable angina within six months of
             visit 1

          9. Resting, sitting blood pressure (BP) &gt; 160mm Hg in systolic pressure or &gt; 100mm Hg is
             diastolic pressure at screening. If a patient is found to have untreated significant
             hypertension at screening and antihypertensive treatment is initiated, assessment for
             study eligibility should be deferred until BP and antihypertensive medication have
             been stable for at least one month. For patients with previously diagnosed
             hypertension, antihypertensive medications must be stable for at least one month prior
             to screening.

         10. Known or suspected cerebrovascular bleeding, hemorrhagic diathesis or incomplete
             hemostasis, and those at high risk of bleeding, have history of a bleeding problem or
             low platelet count or coagulation disorder or are on therapy that affects homeostasis

         11. Active peptic ulcer disease, recent GI bleeding or perforation, or a history of peptic
             ulcers or GI bleeding

         12. History of asthma, urticaria or other allergic-type reaction after taking aspirin or
             other non steroidal inflammatory drugs (NASIDs)

         13. Subject over sixty four (64) years of age

         14. Subject with any clinically significant renal function or liver abnormality

         15. Subject who has history of swelling of face, mouth, tongue, lips, gums, neck, or
             throat (angioedema) or with cardiac decompensation or similar conditions

         16. Major surgery scheduled within 3 weeks or screening and for entire participation of
             study

         17. Current exfoliative dermatitis, Stevens-Johnson syndrome or toxic epidermal necrolysis

         18. Any condition in the opinion of the investigator that makes the subject unsuitable for
             study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward L Davis, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Citrus Valley Medical Research, Inc.</affiliation>
  </overall_official>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2013</study_first_submitted>
  <study_first_submitted_qc>December 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2013</study_first_posted>
  <last_update_submitted>December 3, 2013</last_update_submitted>
  <last_update_submitted_qc>December 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

